Leonard Frank X - Jun 2, 2025 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
EVP, Pres., Novocure Oncology
Signature
Steven Robbins, as attorney in fact for Leonard, Frank X.
Stock symbol
NVCR
Transactions as of
Jun 2, 2025
Transactions value $
-$528,413
Form type
4
Date filed
6/4/2025, 04:09 PM
Previous filing
Mar 6, 2025
Next filing
Jun 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Leonard Frank X EVP, Pres., Novocure Oncology C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE Steven Robbins, as attorney in fact for Leonard, Frank X. 2025-06-04 0001822879

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Sale -$374K -21.7K -10.93% $17.22 177K Jun 2, 2025 Direct F1
transaction NVCR Ordinary Shares Sale -$119K -6.6K -3.73% $17.99 170K Jun 2, 2025 Direct F2
transaction NVCR Ordinary Shares Sale -$35.7K -1.88K -1.1% $19.01 168K Jun 2, 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 21,717 shares in multiple trades at prices ranging from $16.71 to $17.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F2 On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 6,600 shares in multiple trades at prices ranging from $17.71 to $18.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F3 On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 1,879 shares in multiple trades at prices ranging from $18.78 to $19.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.